0.00Open0.05Pre Close0 Volume137 Open Interest45.00Strike Price0.00Turnover0.00%IV72.08%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma523.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Akero Therapeutics Stock Discussion
Akero To Announce SYMMETRY Study Phase 2b Results For Efruxifermin In MASH Cirrhosis; Investor Webcast Set For Jan. 27 At 8 AM ET
Benzinga
·
About the SYMMETRY Study
The Phase 2b SYMMETRY study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in adult patients with biopsy-confirmed compensated cirrhosis (F4, Child-Pugh A) due to MASH. The study enrolled a total of 182 patients, randomized to receive once-weekly subcutaneous dos...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$